Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
P021 is a small-molecule peptide mimetic derived from ciliary neurotrophic factor (CNTF), a member of the neurotrophic cytokine family. In preclinical and animal-model research, P021 has been examined as a compact laboratory tool for probing neurotrophic signaling, with particular attention to the expression of brain-derived neurotrophic factor (BDNF) and cellular processes associated with adult neurogenesis. It is studied strictly as a research compound and is described here for scientific and educational purposes only.
This overview summarizes how P021 has been characterized in the published laboratory literature: its structural origin within the CNTF sequence, the neurotrophic pathways investigated in rodent studies, and observations relating to the tau protein in transgenic animal models. Every statement below reflects preclinical, in-vitro, or animal-model findings. P021 is a research use only compound, not for human consumption, and nothing here should be read as a claim of any human cognitive, clinical, or therapeutic effect.
What Is P021?
P021 belongs to a family of compounds designed to reproduce a functional fragment of ciliary neurotrophic factor in a much smaller and more chemically tractable format. CNTF itself is a large protein that supports the survival and differentiation of certain neurons in laboratory systems, but its size and pharmacological profile make the intact molecule difficult to work with. P021 was developed as a low-molecular-weight peptidomimetic intended to retain a defined region of neurotrophic activity while remaining small enough to cross biological membranes in experimental settings.
Origins in Ciliary Neurotrophic Factor
The compound traces back to an 11-residue peptide fragment (frequently referenced in the literature as Peptide 6) corresponding to a segment of the human CNTF sequence. Structure-activity studies narrowed the active portion to a short core, which was then chemically modified, including the addition of an adamantane group to improve stability and membrane permeability. The result is a modified tetrapeptide-derived molecule rather than a full-length protein.
A Small-Molecule Peptidomimetic
Because of this design, P021 is generally grouped with neurotrophic peptide mimetics rather than with classical signaling peptides. The identity attributes below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported detail |
|---|---|
| Compound designation | P021 (CNTF-derived peptide mimetic) |
| Parent molecule | Ciliary neurotrophic factor (CNTF) |
| Structural origin | Modified core from an 11-residue CNTF fragment (Peptide 6) |
| Core sequence length | Tetrapeptide core (Asp-Gly-Gly-Leu) with adamantane modification |
| Approximate molecular weight | Around 500 Da (small-molecule peptidomimetic) |
| Compound class | Neurotrophic peptide mimetic |
| Research status | Preclinical and laboratory research only |
Neurotrophic Signaling Studied in Preclinical Models
The primary reason P021 has attracted laboratory interest is its reported influence on neurotrophic signaling in rodent studies. Neurotrophins are a group of proteins, including BDNF, that support neuronal survival, synaptic plasticity, and the maturation of newly formed neurons in experimental systems.
BDNF and Neurotrophin Expression
In several animal-model reports, administration of P021 has been associated with increased expression of BDNF in brain regions such as the hippocampus. Because BDNF is a central mediator of synaptic plasticity in preclinical neuroscience, researchers have used P021 as a probe for asking how CNTF-derived signaling intersects with the wider neurotrophin network. These observations are confined to animal tissue and cell-based assays.
Adult Hippocampal Neurogenesis
A related line of investigation concerns neurogenesis, the generation of new neurons in the dentate gyrus of the hippocampus in adult rodents. Studies have reported that P021 is associated with markers of increased neurogenesis and dendritic development in mouse models. Within the research framing, these findings are treated as measurements of cellular activity in animals, not as evidence of any functional outcome in humans.
Tau Biology and Neuronal Studies in Animal Models
A second major theme in the P021 literature involves tau, a microtubule-associated protein that becomes abnormally phosphorylated in a number of experimental models of neurodegeneration. This work is conducted entirely in transgenic animals and cell systems.
Tau Phosphorylation in Transgenic Mice
Investigators have reported that P021 is associated with reduced tau hyperphosphorylation in transgenic mouse models engineered to overexpress human tau or amyloid-related transgenes. One proposed mechanism links the compound to modulation of glycogen synthase kinase-3 beta (GSK-3 beta), an enzyme that phosphorylates tau in laboratory assays. These are biochemical measurements taken in animal tissue.
Model Systems
P021 has been examined across several rodent model systems, including transgenic models used in Alzheimer-type neurodegeneration research and Down-syndrome-related (Ts65Dn) mice, which serve in basic research to study neurodevelopmental and neurodegenerative processes. The compound functions in these settings purely as an experimental agent. To reiterate the compliance framing that applies throughout this article, none of these animal findings should be interpreted as demonstrating a human cognitive, clinical, or therapeutic effect.
P021 Compared to Other Neuroactive Research Peptides
P021 is one of several peptides studied in the broader nootropic and neurotrophic research space. It can be informative to place it alongside other well-characterized research peptides that also intersect with BDNF and neuromodulatory pathways, such as Semax and Selank. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Compound | Reported class | Pathways studied (preclinical) | Approx. molecular weight |
|---|---|---|---|
| P021 | CNTF-derived peptidomimetic | Neurotrophic signaling, BDNF, neurogenesis, tau (animal models) | Around 500 Da |
| Semax | ACTH(4-10)-derived heptapeptide | BDNF and neurotrophin expression, neuromodulation (animal models) | Around 800 Da |
| Selank | Tuftsin-derived heptapeptide | GABA and serotonin systems, BDNF (animal models) | Around 750 Da |
Comparisons of this kind are useful for orienting a research program, but they do not imply equivalence of activity or any shared outcome. Each compound has its own distinct structural origin and its own body of preclinical evidence, and related neuroactive compounds can be found in the broader research peptides catalog. Verifying the identity and purity of any research peptide through a current certificate of analysis remains an essential first step, and the COA purity guide explains how to interpret those documents.
Frequently Asked Questions
What is P021 peptide?
P021 is a small-molecule peptide mimetic derived from ciliary neurotrophic factor (CNTF). It is studied in preclinical and animal-model research as a tool for investigating neurotrophic signaling, including BDNF expression and neurogenesis. It is a research use only compound and is not intended for human consumption.
How is P021 derived from CNTF?
P021 originates from a short fragment of the CNTF protein sequence (an 11-residue region often called Peptide 6). Structure-activity work narrowed this to a tetrapeptide core that was chemically modified, including an adamantane group, to create a compact and more stable peptidomimetic for laboratory use.
What does P021 do to BDNF in research models?
In animal-model studies, P021 has been associated with increased expression of brain-derived neurotrophic factor (BDNF) in brain regions such as the hippocampus. These are measurements taken in rodent tissue and are not evidence of any effect in humans.
Has P021 been studied in relation to tau?
Yes. In transgenic animal models, researchers have reported that P021 is associated with reduced tau hyperphosphorylation, with one proposed mechanism involving modulation of GSK-3 beta activity. This work is entirely preclinical and biochemical.
Is P021 approved for human use?
No. P021 is a research compound described strictly within a preclinical and laboratory context. It is provided for research use only, not for human consumption, self-administration, or therapeutic use.
How does P021 compare to Semax and Selank?
All three are peptides studied in neurotrophic and nootropic research, and each has been linked to BDNF-related pathways in animal models. However, they differ in structural origin: P021 is CNTF-derived, while Semax and Selank derive from ACTH(4-10) and tuftsin sequences respectively. They are distinct compounds with separate bodies of preclinical evidence.
References and Further Reading
- Iqbal K, Liu F, Grundke-Iqbal I, and colleagues at the New York State Institute for Basic Research have published extensively on CNTF-derived peptide mimetics and tau biology. PubMed: P021 CNTF peptide neurogenesis
- Preclinical reports on P021 and BDNF expression in rodent hippocampus. PubMed: P021 BDNF hippocampus
- Animal-model studies of P021 and tau phosphorylation. PubMed: P021 tau phosphorylation
- Background literature on ciliary neurotrophic factor and neuroprotection in laboratory systems. PubMed: ciliary neurotrophic factor neuroprotection
- Reviews of BDNF and adult hippocampal neurogenesis in animal models. PubMed: BDNF adult hippocampal neurogenesis
- Studies of GSK-3 beta and tau in preclinical neurodegeneration models. PubMed: GSK-3 beta tau phosphorylation
- For sourcing and documentation context, see guidance on selecting a research peptide supplier. Rejuven8: How to choose a research peptide supplier
